Welcome to our dedicated page for Alamar Biosciences news (Ticker: ALMR), a resource for investors and traders seeking the latest updates and insights on Alamar Biosciences stock.
Alamar Biosciences reports company developments tied to its Precision Proteomics platform, NULISA technology, and commercialization of instruments, consumables, assays, panels, and services for protein biomarker analysis. Recurring updates include financial results, product launches such as NULISAseq and NULISAqpcr offerings, platform adoption among research and biopharma customers, and public-company milestones following its Nasdaq listing.
Company news also covers healthcare conference participation and corporate updates related to the business model for proteomics tools used in disease research and early-detection applications.
Alamar Biosciences (Nasdaq: ALMR) announced that its management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The company is scheduled for a fireside chat on Tuesday, September 15, at 4:05 p.m. Eastern Time, with live and archived webcasts available via its investors website.
Alamar Biosciences (Nasdaq: ALMR) reported second quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, driven by 35% instrument growth to $7.8 million, 147% consumable growth to $15.5 million, and 49% services and other growth to $6.2 million.
Gross margin improved to 60% from 53%, while operating expenses rose 89% to $31.2 million, leading to an operating loss of $13.5 million and net loss of $13.2 million. Cash, cash equivalents, short-term investments and restricted cash totaled $256.3 million at June 30, 2026.
The company launched the NULISAseq Neuro 220 Panel with an eMTBR-tau assay, the Immune 340 Panel, and expanded its partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. Alamar provided full-year 2026 revenue guidance of $116–$120 million, implying 59% year-over-year growth at the midpoint.
Alamar Biosciences (Nasdaq: ALMR) announced an expanded global partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures to apply its NULISAseq Neuro 220 multiplex protein panel to an additional 86,000 plasma samples. About 21,000 of these are from a national-scale proteomics initiative begun in mid-July 2026.
This builds on a June 2025 multi-center effort that profiled over 55,000 samples with Alamar’s NULISA technology. The combined dataset is projected for completion in 2027 and is expected to exceed 140,000 samples across multiple geographies and cohorts, linked to clinical and longitudinal outcomes and shared via AD Data Initiative infrastructure.
Alamar Biosciences (Nasdaq: ALMR) launched the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling solution for translational research and drug development. The assay measures about 340 immune-related proteins from a single sample, expanding on the earlier NULISAseq Inflammation Panel 250.
According to Alamar Biosciences, the panel’s ultra-sensitive technology detects low-abundance cytokines, chemokines, checkpoint regulators, and cell death markers at fg/mL to sub-pg/mL levels, supporting research in cancer, cardiovascular and metabolic diseases, autoimmune diseases, and aging, including “inflammaging.” A Sanofi biomarker lead highlighted its combined breadth and sensitivity for immune landscape profiling.
Alamar Biosciences (Nasdaq: ALMR) announced it will report its second quarter 2026 financial results after market close on Monday, August 10, 2026. Management will host a webcast conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible via the Investors section of the company website, with an archived replay available.
Alamar Biosciences (Nasdaq: ALMR) announced a national proteomics initiative with leading U.S. research universities to profile about 21,000 plasma samples from 10,000 Alzheimer’s Disease Research Center participants using its NULISAseq™ Neuro 220 panel, including a new eMTBR-Tau assay capturing tau tangle burden and multiple neurodegeneration pathways.
The project, part of the CLARiTI portfolio and supported by philanthropic and data-sharing partners, will generate an open, publicly accessible proteomic dataset linked to NACC IDs, enabling AI-driven multimodal analyses to support biomarker discovery, disease classification, and prediction of neurodegenerative disease progression.
Alamar Biosciences (Nasdaq: ALMR) announced that its NULISA™ precision proteomics platform will appear in more than 140 posters and sessions at the Alzheimer’s Association International Conference (AAIC) 2026 in London, July 12‑15, reflecting broad research use in Alzheimer’s and related dementias.
The company will host a workshop, “Beyond p-tau217: Expanding Alzheimer's Insights with Multiplex Protein Profiling,” on July 14, 1:20–2:00 PM BST, highlighting eMTBR-Tau and BD-pTau217 assays, their use alongside over 220 disease-related proteins, and applications across presymptomatic to diagnosed populations.
Alamar Biosciences (Nasdaq: ALMR) launched the first commercial eMTBR-Tau blood immunoassay, a non-invasive test reflecting tau tangle pathology in Alzheimer’s disease. The assay is available within the NULISAseq Neuro 220 multiplexed panel, deployable on all ARGO HT instruments, and as a single-plex assay via the Technology Access Program.
The eMTBR-Tau assay targets an MTBR fragment generated at site 256, offers attomolar sensitivity, and can be run alongside other neurodegeneration and neuroinflammation biomarkers from a low-volume sample. According to Alamar, data on analytical performance and clinical findings will be presented at an AAIC 2026 workshop in London.
Alamar Biosciences (Nasdaq: ALMR) reported Q1 2026 revenue of $26.0 million, a 99% increase year-over-year, driven by instrument placements and consumable pull-through. Gross margin improved to 56% from 49% due to higher volumes and favorable product mix.
Operating loss was $12.3 million and net loss was $21.3 million, which included an $8.6 million remeasurement of convertible notes. After quarter end, the company completed an IPO, generating $197.8 million net proceeds, and held $69.5 million in cash and equivalents as of March 31, 2026.
Alamar Biosciences (Nasdaq: ALMR) will present at the BofA Securities 2026 Healthcare Conference in Las Vegas on Tuesday, May 12, 2026 at 3:40 p.m. PT / 6:40 p.m. ET. A live and archived webcast will be available in the Investors section at investors.alamarbio.com.